Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

"News of medicine and pharmacy" №7 (694), 2019

Back to issue

Прогностические биохимические маркеры преэклампсии

Authors: Мельник А.А.,
к.б.н., руководитель проекта специализированного медицинского центра «Оптима Фарм», г. Киев, Украина

Categories: Obstetrics and gynecology, Urology

Sections: Specialist manual

print version

Преэклампсия (ПЭ) — мультисистемное патологическое состояние, возникающее во второй половине беременности (после 20-й недели), характеризующееся артериальной гипертензией de novo (≥ 140/90 мм рт.ст.) в сочетании с протеинурией (≥ 0,3 г/л в суточной пробе) и проявлениями полиорганной недостаточности [1, 2]. Ежегодно в мире регистрируется более 8 миллионов случаев преэклампсии, от чего умирают 60 000 женщин [3]. Фактически в структуре акушерских причин материнской смертности преэклампсия занимает второе место после тромбоэмболических осложнений. Частота ПЭ достигает 3–8 % от всех беременностей с существенными различиями в зависимости от страны проживания [4]. Так, в развивающихся странах с ограниченным доступом к высококачественной медицинской помощи показатели смертности ...


For the full article you need to subscribe to the magazine.


Bibliography

1. ACOG. ACOG practice bulletin. Diagnosis and ma-nagement of preeclampsia and eclampsia // Obstetrics and gynecology. — Jan 2002. — 99(1). — Р. 159-167.

2. Magee L.A., Pels A., Helewa M., Rey E., von Dadelszen P.; Group CHDoPW. Diagnosis, evaluation, and ma-nagement of the hypertensive disorders of pregnancy // Pregnancy hypertension. — 2014. — 4(2). — Р. 105-45.

3. WHO. The World Health Report 2005: Make every mother and child count. — Geneva. WHO, 2005.

4. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia // Lancet. — 2005. — 365(9461). — Р. 785-99.

5. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia // Seminars in perinatology. — 2012. — 36(1). — Р. 56-9.

6. Sween L.K., Althouse A.D., Roberts J.M. Early-pregnancy percent body fat in relation to preeclampsia risk in obese women // Am. J. Obstet. Gynecol. — 2014.

7. National Collaborating Centre for Women’s and Children’s Health (UK), Hypertension in Pregnancy: The Ma-nagement of Hypertensive Disorders During Pregnancy. — RCOG Press, London, UK, 2010.

8. World Health Organization, Department of Reproductive Health and Research, Department of Maternal, Newborn, Child and Adolescent Health, and Department of Nutrition for Health and Development, WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia,World Health Organization, 2011.

9. Magee L.A., Helewa M., Moutquin J.M., von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy // Journal of Obstetrics & Gynaecology. — 2008. — Vol. 30, № 3 (suppl.). — Р. S1-S48.

10. American College of Obstetricians and Gynecologists, and Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy // Obstetrics and Gynecology. — 2013. — Vol. 122, № 5. — Р. 1122-1131.

11. Shenoy V. Preeclampsia: connecting angiogenic and metabolic pathways / V. Shenoy, K. Kanasaki, R. Kalluri // Trends Endocrinol. Metab. — 2010. — Vol. 21, № 9. — Р. 529-536.

12. Redman C.W. Placental stress and preeclampsia: a revised view / C.W. Redman, I.L. Sargent // Placenta. — 2009. — Vol. 30. — P. 38-42.

13. Roberts J.M. The Two Stage Model of Preeclampsia: Variations on the Theme / J.M. Roberts, C.A. Hubel // Placenta. — 2009. — Vol. 23. — P. 32-33.

14. Lee S.M. et al. Systemic inflammatory stimulation by microparticles derived from hypoxic trophoblast as a model for inflammatory response in preeclampsia // Am. J. Obstet. Gynecol. — 2012. — Vol. 207, № 4. — P. 337-346.

15. Harris L.K. Association of inflammatory cytokines, lipid peroxidation end products and nitric oxide with the clinical severity and fetal outcome in preeclampsia in Indian women // Indian J. Clin. Biochem. — 2014. — Vol. 29, № 2. — Р. 139-144.

16. Hyde C., Thornton S. Does screening for pre-eclampsia make sense? // BJOG. — 2013. — 120(10). — Р. 1168-70.

17. North R.A., McCowan L.M., Dekker G.A., Poston L., Chan E.H., Stewart A.W. et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort // BMJ. — 2011. — 7(342). — d1875.

18. Сarty D., Delles C., Dominiczak A. Novel Biomar-kers for Predicting Preeclampsia // Cardiovasc. Med. — 2008. — 18. — Р. 186-194.

19. Pensée Wu, Caroline van den Berg, Zarko Alfirevic et al. Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis // Int. J. Mol. Sci. — 2015. — 16. — Р. 23035-23056.

20. Ghosh S.K., Raheja S., Tuli A., Raghunandan C., Agarwal S. Can maternal serum placental growth factor estimation in early second trimester predict the occurrence of early onset preeclampsia and/or early onset intrauterine growth restriction? A prospective cohort study // J. Obstet. Gynaecol. Res. — 2013. — 39(5). — Р. 881-890.

21. McElrath T., Lim K., Pare E., Rich-Edwards J., Pucci D., Troisi R. et al. Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy // Am. J. Obstet. Gynecol. — 2012. — 207(5). — 407. — e1-e7.

22. De Falco S. The discovery of placenta growth factor and its biological activity// Experimantal and Molecular Medicine. — 2012. — Vol. 44, № 1. — P. 1-9.

23. Muy-Rivera M., Vadachkoria S., Woelk G.B
et al. Maternal Plasma VEGF, sVEGF-R1 and PlGF Concentrations in Preeclamptic and Normotensive Pregnant Zimbabwean Women // Physiol.Res. — 2005. — Vol. 54. — P. 611-622.

24. Chappell L.C., Duckworth S., Seed P.T., Griffin M., Myers J., Mackillop L. et al. Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia: A Prospective Multicenter Study // Circulation. — 2013. — 128(19). — Р. 2121-2131.

25. Kar M. Role of biomarkers in early detection of preeclampsia // J. Clin. Diagn. Res. — 2014. — 8. — BE01-4.

26. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. Circulating angiogenic factors and the risk of preeclampsia // N. Engl. J. Med. — 2004. — 350. — Р. 672-83.

27. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia // J. Clin. Invest. — 2003. — 111. — Р. 649-58.

28. Verlohren S. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients // Am. J. Obstet. Gynecol. — 2012. — Vol. 206. — P. 58.

29. Rana S. et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile // Hypert. Pregn. — 2013. — Vol. 32(2). — P. 189-201.

30. Verlohren S. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia // Am. J. Obstet. Gynecol. — 2010. — Vol. 202(161). — P. 1-11.

31. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P. et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for pre-eclampsia // Hypertension. — 2014. — 63(2). — Р. 346-52.

32. Rana S., Powe C.E., Salahuddin S., Verlohren S., Perschel F.H., Levine R.J. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia // Circulation. — 2012. — 125. — Р. 911-9.

33. NICE Guidance. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) // Diagnostics Guidance. — 2016. — 23.

34. Mutter W.P., Karumanchi S.A. Molecular mechanisms of preeclampsia // Microvas. Res. — 2008. — 75. — Р. 1-8.

35. Robinson C.J., Johnson D.D. Soluble endoglin as a second-trimester marker for preeclampsia // Am. J. Obstet. Gynecol. — 2007. — 197(2). — 174. — e1-5.

36. Bersinger N.A., Smarason A.K., Muttukrishna S. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A, and soluble E-selectin // Hypertens. Pregnancy. — 2003. — 22. — Р. 45-55.

37. Yaron Y., Heifetz S., Ochshorn Y., Lehavi O., Orr-Urteger A. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome // Prenat. Diagn. — 2002. — 22. — Р. 778-82.

38. Poon L.C. et al. First-trimester maternal serum pregnancy-associated plasma protein-A and preeclampsia // Ultrasound Obstet. Gynecol. — 2009. — Vol. 33. — P. 23-33.

39. Poon L.C. et al. Hypertensive disorders in pregnancy: Screening by biophysical and biochemical markers at 11–13 weeks / L.C. Poon [et al.] // Ultrasound Obstet. Gynecol. — 2010. — Vol. 35. — P. 662-670.

40. Akolekar R. et al. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks // Prenat. Diagn. — 2011. — Vol. 31. — P. 66-74.

41. Spencer К. et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of preeclampsia // Ultrasound Obstet. Gynecol. — 2007. — Vol. 29, № 2. — P. 128-134.

42. Khalil А. et al. First trimester maternal serum placental protein 13 for the prediction of preeclampsia in women with a priori high risk // Prenat. Diagn. — 2009. — Vol. 29, № 8. — P. 781-789.

43. Muttukrishna S., North R.A., Morris J. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia // Hum. Reprod. — 2000. — 15. — Р. 1640-5.

44. Muttukrishna S., Knight P.G., Groome N.P. Activin A and inhibin A as possible endocrine markers for pre-eclampsia // Lancet. — 1997. — 349. — Р. 1285-8.

45. Mandang S., Maneulpillai U., Wallace E.M. Oxidative stress increases placental and endothelial cell activin A secretion // J. Endocrinol. — 2007. — 192. — Р. 485-93.

46. Souza D.G., Soares A.C., Pinho V., Torloni H., Reis L.F., Teixeira M.M. et al. Increased mortality and inflammation in tumor necrosis factorstimulated gene-14 transgenic mice after ischemia and reperfusion injury // Am. J. Pathol. — 2002. — 160. — Р. 1755-65.

47. Cetin I., Cozzi V., Pasqualini F., Nebuloni M., Garlanda C., Vago L. et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction // Am. J. Obstet. Gynecol. — 2006. — 194. — Р. 1347-53.

48. Spencer K. ADAM12 sin maternal serum as a potential marker of pre-eclampsia / K. Spencer, N.J. Cowans, A. Stamatopoulou // Prenat. Diagn. — 2008. — Vol. 28. — P. 212-216.

49. Li H. Maternal plasma miRNAs expression in preeclamptic pregnancies / H. Li, Q. Ge, L. Guo, Z. Lu // BioMed Research. Intern. — 2013. — Vol. 2013. — P. 9.

50. Sharma A., Satyam A., Sharma J.B. Leptin, il-10 and inflammatory markers (tnf-alpha, il-6 and il-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women // Am. J. Reprod. Immunol. — 2007. — Vol. 58. — P. 21-30.

51. Herse F. et al. Circulating and uteroplacental adipocytokine concentrations in preeclampsia // Reprod. Sci. — 2009. — Vol. 16. — P. 584-590.

52. Stepan H. et al. Serum levels of the adipokine cheme-rin are increased in preeclampsia during and 6 months after pregnancy / Regul. Pept. — 2011. — Vol. 168. — P. 69-72.

53. Duan D.M. et al. Serum levels of the adipokine chemerin in preeclampsia // J. Perinat. Med. — 2012. — Vol. 40. — P. 121.

54. Thilaganathan B. et al. Raised maternal serum cystatin C: an early pregnancy marker for preeclampsia / Reprod. Sci. — 2009. — Vol. 16. — P. 788-793.

55. Nakatsukasa H., Masuyama H., Takamoto N., Hiramatsu Y. Circulating leptin and angiogenic factors in preeclampsia patients // Endocr. J. — 2008. — Vol. 55. — P. 565-557.

56. Hu W. et al. Serum visfatin levels in late pregnancy and pre-eclampsia // Acta Obstet. Gynecol. Scand. — 2008. — Vol. 87. — P. 413-418.

57. Nagy B., Rigo J., Fintor L. Apolipoprotein E alleles in women with severe pre-eclampsia // J. Clin. Pathol. — 1998. — 51. — Р. 324-325.

58. Makkonen N., Heinonen S., Hiltunen M. et al. Apolipoprotein E alleles in women with pre-eclampsia // J. Clin. Pathol. — 2001. — 54. — Р. 652-654.

59. Belo L., Gaffney D., Caslake M. et al. Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies // Eur. J. Obstet. Gynecol. Reprod. Biol. — 2004. — 112. — Р. 9-15.

60. Galeazzi M. Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders / M. Galeazzi, G. Morozzi, M. Piccini, J. Chen, F. Bellisai, S. Fineschi, R. Marcolongo // Autoimmun. Rev. — 2003. — Vol. 2, № 1. — P. 50-55.

61. Pisetsky D.S. The origin and properties of extracellular DNA: from PAMP to DAMP / D.S. Pisetsky // Clin. Immunol. — 2012. — Vol. 144. — P. 32-40.

62. Scharfe-Nugent A., Corr S.C., Carpenter S.B., Keogh L., Doyle B., Martin C. et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia // J. Immunol. — 2012. — 188. — Р. 5706-12.

63. Miranda M.L., Macher H.C., Muñoz Hernández R., Vallejo-Vaz A., Moreno-Luna R., Villar J. et al. Role of circulating cell-free DNA levels in patients with severe preeclampsia and HELLP syndrome // Am. J. Hypertens. — 2013. — 26. — Р. 1377-80.

64. Lo Y.M., Leung T.N., Tein M.S., Sargent I.L., Zhang J., Lau T.K. et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia // Clin. Chem. — 1999. — 45. — Р. 184-8.

65. Martin A., Krishna I., Badell M., Samuel A. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review // Prenat. Diagn. — 2014. — 34. — Р. 685-91. 

Similar articles

Peripartummanagement of hypertension: a position paper of the ESC Council on Hypertension  and the European Society of Hypertension
Authors: Renata Cífková (1, 2), Mark R. Johnson (3), Thomas Kahan (4), Jana Brguljan (5), Bryan Williams (6), Antonio Coca (7), Athanasios Manolis (8), Costas Thomopoulos (9), Claudio Borghi (10), Costas Tsioufis (11), Gianfranco Parati (12, 13), Isabella Sudano (14), Richard J. McManus (15), Bert-Jan H. van den Born (16), Vera Regitz-Zagrosek (17), and Giovanni de Simone (18)
1) Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Prague 4, Czech Republic;
2) Department of Medicine II, Charles University in Prague, First Faculty of Medicine, Prague, Czech Republic;
3) Institute of Reproductive and Developmental Biology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, UK;
4) Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden;
5) Division of Internal Medicine, Department of Hypertension, Medical Faculty, University Medical Centre Ljubljana, Ljubljana, Slovenia;
6) UCL Institute of Cardiovascular Sciences, University College London, London, UK;
7) Hypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital Clinic, University of Barcelona, Barcelona, Spain;
8) Department of Cardiology, Asklepeion General Hospital, Athens, Greece;
9) Department of Cardiology, Helena Venizelou General & Maternal Hospital, Athens, Greece;
10) Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy;
11) First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece;
12) Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy;
13) Cardiology Unit, Department of Cardiovascular, Neural and Metabolic Sciences, Istituto Auxologico Italiano, IRCCS, S. Luca Hospital, Milan, Italy;
14) Department of Cardiology, University Heart Center Zurich, University Hospital and University of Zurich, Zurich, Switzerland;
15) Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK;
16) Departments of Internal and Vascular Medicine, Department of Public Health, Amsterdam University Medical Centre, Amsterdam, The Netherlands;
17) Berlin Institute for Gender in Medicine and CCR, Charité University Medicine Berlin, and DZHK, Partner Site Berlin, Germany;
18) Department of Advanced Biomedical Sciences, Hypertension Research Center, Federico II University, Naples, Italy

"Hypertension" Том 13, №4, 2020
Date: 2020.09.28
Categories: Cardiology
Sections: Specialist manual
Преэклампсия в клинике экстрагенитальной патологии
Authors: Медведь В.И., д.мед.н., профессор, член-корреспондент НАМН Украины, заведующий отделением внутренней патологии беременных ГУ «Институт педиатрии, акушерства и гинекологии НАМН Украины»; Дуда Е.М., акушер-гинеколог, отделение внутренней патологии беременных ГУ «Институт педиатрии, акушерства и гинекологии НАМН Украины»
"Kidneys" 3 (05) 2013
Date: 2013.08.22
Categories: Obstetrics and gynecology, Nephrology
Sections: Specialist manual
Гормони жирової тканини і гестаційний цукровий діабет
Authors: Паєнок О.С., Коритко О.О. - Національний медичний університет імені Данила Галицького, м. Львів; Петруняк Р.І. - Пологовий будинок, м. Коломия
International journal of endocrinology 7 (55) 2013
Date: 2013.12.25
Categories: Obstetrics and gynecology, Endocrinology
Sections: Specialist manual

Back to issue